
Opinion|Videos|October 7, 2024
Vitiligo Treatment Paradigms: Clinician Experiences with Topical Ruxolitinib and Access Challenges
Author(s)Terry Faleye, MPAS, PA-C
Panelists discuss how their clinical experiences with topical ruxolitinib are shaping new treatment paradigms for vitiligo, while also addressing challenges related to medication access.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
Expert Panel Unanimously Backs DecisionDx-Melanoma for Guiding Personalized Cancer Care
4
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
5



















